Serum vitamin B12 not reflecting vitamin B12 status in patients with type 2 diabetes

Biochimie ◽  
2013 ◽  
Vol 95 (5) ◽  
pp. 1056-1061 ◽  
Author(s):  
Rima Obeid ◽  
John Jung ◽  
Julia Falk ◽  
Wolfgang Herrmann ◽  
Jürgen Geisel ◽  
...  
2017 ◽  
Vol 4 (90) ◽  
pp. 5399-5404
Author(s):  
Anand Kalakappa Koppad ◽  
Gavisiddanagowda Patil ◽  
Basavaraj Devendrappa Baligar ◽  
Varun Bhaktarahalli Renukappa

Background: Vitamin B12 deficiency may be related to peripheral neuropathy in people with type 2 diabetes mellitus (T2DM). Level of B12 in T2DM observed by many investigators showed variable results. Studies on vitamin B12 in T2DM are very limited in Bangladesh. Objectives: To observe serum vitamin B12 level in newly diagnosed T2DM patients. Methods: Observational cross-sectional study encompassing 50 newly diagnosed T2DM and 50 controls as per American Diabetes Association (ADA) criteria. Vitamin B12 and Hemoglobin A1c (HbA1c) were measured for all. Results: Both mean (492.46±28.82 vs. 346.48±19.65 pg/mL, mean±SEM; p=<0.001) and median (435.50 vs. 334.50 pg/mL) values of serum vitamin B12 were found to be higher in T2DM than those of controls. None of the diabetic subjects were found to be B12 deficient whereas 6 were borderline deficient; these frequencies were 7 and 11 respectively among the controls. Vitamin B12 level was statistically similar in patients with or without clinically evident peripheral neuropathy (mean±SEM; 523.48±39.39 vs. 441.84±38.76 pg/mL, p=0.172). B12 level showed positive correlation with fasting plasma glucose (FPG, r=0.285, p=0.061) and HbA1c (r=0.287, p= 0.043) in diabetes group but there was no correlation with body mass index (BMI). Conclusion: Vitamin B12 is found sufficient in newly diagnosed Bangladeshi T2DM patients.


2008 ◽  
Vol 18 (2) ◽  
pp. 226-232 ◽  
Author(s):  
E. Aydin ◽  
H.D. Demir ◽  
H. Ozyurt ◽  
I. Etikan

Purpose The aim of this study was to assess the association of macular edema (ME) with plasma homocysteine, vitamin B6, vitamin B12, and folic acid levels in patients with Type 2 diabetes. Methods Sixty-five diabetic subjects with no retinopathy and nonproliferative diabetic retinopathy (NPDR) (no DR, without ME, with ME: 16, 25, 24, respectively), 28 with proliferative diabetic retinopathy (PDR) (with and without ME: 14, 14, respectively), and 19 healthy subjects as control were recruited in this cross-sectional study Plasma homocysteine, vitamin B12, vitamin B6, and folate levels were determined after 8-hour of fasting for all subjects. The levels of serum homocysteine and vitamin B6 were measured using high performance liquid chromatography (HPLC) with fluorescence detection, and the levels of serum vitamin B12 and folic acid were measured by electrochemiluminescence immunoassay. Results When diabetic groups with ME were compared with diabetic groups without ME for homocysteine, vitamin B12, vitamin B6, and folic acid, the only significant difference was detected in homocysteine levels (p=0.001). There was no significant difference between NPDR with ME group compared with NPDR without ME group and no DR group for plasma homocysteine, vitamin B12, vitamin B6, and folic acid (p=0.200, p=0.660; p=0.999, p=0.678; p=1.0, p=0.248; p=1.0, p=0.982, respectively). On the other hand, when PDR with ME group was compared with PDR without ME group, there was only significant difference in homocysteine levels (p=0.023). Conclusions Mild to moderate elevation of homocysteine may explain the role of vascular dysregulation and endothelial dysfunction in patients with DR. The present study suggests hyperhomocysteinemia may be one of the crucial risk factors for development of ME.


2021 ◽  
Author(s):  
◽  
Sylvan Haeusler

<p>With an ever increasing incidence of type 2 diabetes in the New Zealand population, continual assessment must be made to ensure the ongoing evaluation of treatment options to ensure patient care is not compromised. Previous research has shown higher prevalence of Vitamin B12 deficiency in patients with type 2 Diabetes Mellitus who have had long term metformin treatment. An investigation into patients attending secondary care clinics at the Diabetes Clinic at Wellington Regional Hospital as well as primary health care patients has explored the prevalence of this interaction in the New Zealand population as well as assessed the factors that may contributed to such an effect. It was found that there is a high prevalence of decreased serum Vitamin B12 level in patients with type 2 Diabetes exposed to metformin treatment. Factors such as age and ethnicity were seen to be key predictors of this interaction and have shown a unique view of how the population of New Zealand may be affected. Treatment of decreased serum Vitamin B12 levels was seen to be effective through both sublingual and intramuscular methods with variations in both short and long term effects. The use of sublingual treatment administration of Vitamin B12 supplementation is unique in the scope of metformin induced Vitamin B12 deficiency and has shown potential to be a therapeutic route for patients affected by such an interactions. Current views on the interaction between metformin and serum Vitamin B12 levels are currently under debate in regards to physiological relevance and clinical outcomes. This paper provides a first look at the effect of this interaction in a New Zealand population and evaluates treatment options for such. Furthermore a proposal is made for an alternate mechanism of metformin action on Vitamin B12 levels which may aid understanding of observations made in both in this paper and previous studies.</p>


2021 ◽  
Vol 8 (31) ◽  
pp. 2835-2841
Author(s):  
Priyadharshini Kannan ◽  
Sivaa Rajendran ◽  
Sunil Kumar Nanda ◽  
Vasanthi Natarajan

BACKGROUND Metformin is considered as a cornerstone in the treatment of diabetes and is the most frequently prescribed first line therapy for individuals with T2DM. Metformin use in type 2 diabetes mellitus has shown to cause vitamin B12 (B12) deficiency. Besides these, B12 deficiency related neuropathy may mimic and/or aggravate the underlying diabetic neuropathy. Furthermore, there have been lack of consensus regarding the universal routine screening of serum B12 levels among metformin users with T2DM, and similar studies from India are also limited. So, we wanted to study the relationship between metformin use and serum B12 in T2DM patients. METHODS The study included a total of 104 subjects of which 52 are T2DM affected individuals who are only on metformin therapy for at least 3 months, served as cases and 52 are newly diagnosed T2DM age and sex matched individuals yet to be medically treated, served as controls. Their blood samples were collected to estimate vitamin B12 and other parameters. RESULTS The median B12 levels in cases 213.5 pg/mL (IQR 136.25-301.0) were found to be significantly lower (P < 0.05) when compared to median levels of controls 240 pg/mL (IQR 214-303.25). B12 levels also showed a significant fall in their levels with increasing duration of T2DM. CONCLUSIONS Metformin induced vitamin B12 deficiency plays a major role in developing life risks in T2DM patients. Routine screening and supplementation of B12 may be required in T2DM patients KEYWORDS Metformin, Type 2 Diabetes Mellitus, Vitamin B12


Sign in / Sign up

Export Citation Format

Share Document